ERBB2 and neoplasm: Since MAP30 can reduce HER2 expression, leading to decreased Fn14 expression, and hSGZ can target Fn14-positive cells and exert its function without increasing the invasive capacity of tumor cells, we hypothesize that using them together might achieve a better outcome, and breast tumor cells can be sequentially treated with MAP30 and hSGZ.